

| Catalog No. | DS856018 |
|---|---|
| Description |
Afasevikumab ELISA Kit (DS856018) — Quantitative sandwich ELISA for Afasevikumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
|
| Sample type | Plasma, Serum |
| Sensitivity | 0.156 μg/ml |
| Range | 0.31-5 μg/mL |
| Accession | Q16552 & Q96PD4 |
| Applications | ELISA |
| Detection method | Colorimetric |
| Assay type | Quantitative |
| Recovery | 80-120% |
| Shipping | 2-8 ℃ |
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Specifications | Afasevikumab |
| Alternate Names | MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9 |
| Background | Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. |
| Note | For Research Use Only. |



Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com
+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский